Interestingly 9/17 (59%) cancers that were treated with trastuzumab alone showed a significant decrease in p-AKT levels and 4/9 had a pCR, whereas only 2/9 (22.2%) tumours treated with trastuzumab and lapatinib showed decreased p-AKT post-treatment and both had a pCR. Here, AKT1 is linked to cancer.